早期大剂量丙种球蛋白治疗新生儿ABO溶血病的临床研究

目的:探讨早期大剂量静脉用丙种球蛋白(IVIG)治疗新生儿ABO溶血病的临床效果。方法:将60例新生儿ABO溶血病患儿随机分为IVIG组和对照组,对照组给予常规治疗,IVIG组在对照组基础上给予大剂量丙种球蛋白1g/(kg.d)静脉滴注,连用1～3d。观察血清总胆红素动态变化、黄疸消退时间、住院时间。结果:IVIG组治疗后24小时、72小时后血清总胆红素值较对照组明显降低(P<0.01);黄疸消退时间明显缩短(P<0.01);住院时间明显缩短(P<0.01)。结论:早期大剂量丙种球蛋白能阻断新生儿ABO溶血病的溶血过程,可降低血清胆红素水平,缩短疗程。

Clinical Study of a Great Quantity Gammavenin(IVIG) on Newborn ABO Hemolytic Disease in Early Stage

Objective:It is to discuss the clinical effect of a great quantity Gammavenin(IVIG) on newborn ABO hemolytic disease in early stage.Methods:60 newborns with ABO hemolytic disease were randomly divided into IVIG group ang control group.Control group was treated with conventional treatment.On the basis of control group,IVIG group was added IVIG.The dynamic change of serum total bilirubin and the time of jaundice,the length of stay.Results:The serum total bilirubin in IVIG group at 24h,72h after treatment were obviously lower than in control group(P<0.01);the time of jaundice in IVIG group after treatment were obviously shorter than in control group(P<0.01);the length of stay were obviously shorter than in control group(P<0.01).Concluslon:Early stage a great quantity Gammavenin(IVIG) on newborn ABO hemolytic disease can block haemolytic procedure of newborn ABO hemolytic disease,lower serum bilirubin level and shorten the course treatment.